Dehydroepiandrosterone for systemic lupus erythematosus

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Crosbie, David ^a   Black, C ^b   McIntyre, L ^b   Royle, P L ^b   Thomas, S ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b NONE

Author keywords

Adjuvants, immunologic *therapeutic use ; Dehydroepiandrosterone *therapeutic use ; Humans; Lupus erythematosus, systemic *drug therapy ; Randomized controlled trials as topic

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; GLUCOCORTICOID; HYDROXYCHLOROQUINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRASTERONE; PREDNISOLONE; PREDNISONE; STEROID; VITAMIN D;

ABDOMINAL PAIN; ACNE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HIRSUTISM; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MENSTRUATION; MOOD CHANGE; MUSCULOSKELETAL DISEASE; NEOPLASM; NONHUMAN; OSTEOPOROSIS; PATIENT ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SHORT FORM 36; SIDE EFFECT; SINUSITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 40849122905     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005114.pub2     Document Type: Review

References (49)

1. Chang 2002 {published data only} Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2002;46(11):2924-7.
2. Hartkamp 2004 {published data only} Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis and Rheumatism 2004;50(11):3591-5.
3. Nordmark 2005 {published data only} Nordmark G, Bengtsson C, Larsson A, Karlsson FA, Sturfelt G, Ronnblom L. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity 2005;38(7):531-40.
4. Petri 2002 {published data only} Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, Strand V, Kunz A, Gorelick KJ, Schwartz KE, -Study-Group. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism 2002;46(7): 1820-9.
5. Petri 2004 {published data only} Mease PJ, Ginzler EM, Gluck OS, Schiff M, Goldman A, Greenwald M, Cohen S, Egan R, Quarles BJ, Schwartz KE. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy. Journal of Rheumatology 2005;32(4):616-21.
6. *Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis and Rheumatism2004;50(9):2858-68.
7. Van Vollenhoven 1995 {published data only} vanVollenhoven RF, Engleman EG, Lambert RE, Lee YSL, McGuire JL. Treatment of Systemic Lupus-Erythematosus with Dehydroepiandrosterone - Interim Analysis of A Double-Blinded, Randomized, Placebo-Controlled, Clinical-Trial. Arthritis and Rheumatism 1993;36(9 Suppl S Sep):S92.
8. *Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis and Rheumatism 1995;38(12):1826-1831.
9. vanVollenhoven RF, Lambert RE, Lee YSL, McGuire JL, Engleman EG. Treatment of Systemic Lupus-Erythematosus with Dehydroepiandrosterone Follow-Up from An Open-Label Clinical- Trial. Arthritis and Rheumatism 1993;36(9 Suppl S):S228.
10. Van Vollenhoven 1999 {published data only} Van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 1999;8(3):181-187.
11. Barry 1998 Barry NN, McGuire JL, Van Vollenhoven RF. Dehydroepiandrosterone in systemic lupus erythematosus: Relationship between dosage, serum levels, and clinical response. Journal of Rheumatology 1998;25(12):2352-6.
12. Chang 2004 Chang DM, Chu SJ, Chen HC, Kuo SY, Lai JH. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. Annals of Rheumatic Diseases 2004;63(12):1623-6.
13. van Vollenhoven 1992 van Vollenhoven RF, Lee YSL, Lambert RE, Engleman EG, Mcdevitt HO, McGuire JL. Treatment of Systemic Lupus-Erythematosus with Dehydroepiandrosterone - A Pilot-Study. Arthritis and Rheumatism 1992;35(9 Suppl S):S55.
14. van Vollenhoven 1993 van Vollenhoven RF, Lambert RE, Lee YSL, McGuire JL, Engleman EG. Treatment of Systemic Lupus-Erythematosus with Dehydroepiandrosterone Follow-Up from An Open-Label Clinical- Trial. Arthritis and Rheumatism 1993;36(9 Suppl S):S228.
15. van Vollenhoven 1994 Van Vollenhoven RF, Engleman EG, McGuire JL. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis and Rheumatism 1994;37(9):1305-10.
16. van Vollenhoven 1996 van Vollenhoven RF. Increased bone mineral density in patients with SLE treated with DHEA. Arthritis and Rheumatism 1996;39(9 Suppl S Sep):1588.
17. van Vollenhoven 2001 van Vollenhoven RF. Dehydroepiandrosterone improves cognitive function in patients with systemic lupus erythematosus: Results of a double-blinded, placebo controlled pilot study. Lupus 2001;10(Supplement 1):S51.
18. vanVollenhoven 1994b Van Vollenhoven R, Morabito L, Engleman E, Lambert R, Lee Y, S, McGuire J, L. Treatment of systemic lupus erythematosus with dehydroepiandrosterone, two-year follow-up from an open-label clinical trial. Arthritis and Rheumatism 1994;37(9 SUPPL.):S407.
19. Boumpas 1992 Boumpas DT, Austin HA, Vaughn E, Klippel JH, Steinberg AD, Yarboro CH, Barlow JE. Controlled Trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5. [MEDLINE: 54].
20. Caccavo 1997 Caccavo D, Lagana B, Mitterhofer AP, Ferri GM, Afeltra A, Amoroso A, Bonomo L. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis and Rheumatism 1997;40:27-35.
21. Cates 2003 Dr Chris Cates. EBM Website. www.nntonline.net 2003.
22. CDER 2005 Center for Drug Evaluation and Research (CDER). Guidance for Industry: Systemic Lupus Erythematosus - Developing Drugs for Treatment. U.S. Department of Health and Human Services UFood and Drug Administration, U.S. Department of Health and Human Services 2005.
23. CHSG 1991 Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulphate in systemic lupus erythematosus. New England Journal of Medicine 1991;324:150-4. [MEDLINE: 51].
24. Derksen 1998 Derksen RHWM. Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus. Seminars in Arthritis and Rheumatism1998;27:335-47. [MEDLINE: 63].
25. FitzGerald 1999 FitzGerald JD, Grossman JM. Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. Lupus 1999;8(8):638-44.
26. Genelabs 2001 Genelabs Technologies I. GL701 (DHEA, prasterone) for the treatment of systemic lupus erythematosus (SLE) in women. Briefing Document FDA Arthritis Advisory Committee 2001; Vol. Briefing Document, FDA Arthritis Advisory Committee.[MEDLINE: 64].
27. Hart 1983 Hart HH, Grigor RR, Caughey DE. Ethnic difference in the prevalence of systemic lupus erythematosus. Annals of Rheumatic Diseases 1983;42(5):529-32.
28. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. John Wiley & Sons, Ltd. Chichester, UK.
29. Homik 2004 Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, Suarez-Almazor M. Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews 1999;Issue 1(CD001347). [MEDLINE: 53].
30. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
31. Johnson 1995 Johnson AE, Gordon C, Palmer RG, Baethge BA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis and Rheumatism 1995;38(4):551-8. [MEDLINE: 61].
32. Johnson 1996 Johnson AE, Gordon C, Hobbs FDR, Baethge BA. Undiagnsoed systemic lupus erythematosus in the community. Lancet 1996;347:367-9. [MEDLINE: 62].
33. Khan 2000 Khan KS, ter Riet G, Glanville J, Sowden A, Kleijnen J. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out and commissioning reviews. 2000; Vol. CRD Report 4 (2nd edition).
34. Kingdon 2001 Kingdon EJ, McLean AG, Psimenou E, Davenport A, Powis SH, Sweny P, Burns A. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001;10(9):606-11.
35. Lee 1993 Lee SS, Li CS, Li PCK. Clinical profile of Chinese patients with systemic lupus erythematosis. Lupus 1993;2:105-9. [MEDLINE: 48].
36. McCarty 1995 McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis and Rheumatism 1995;38(9):1260-70.
37. Mok 2003 Mok CC, Lau CS. Lupus in Hong Kong Chinese. Lupus 2003;12(9):717-22.
38. Nived 1997 Nived O, Sturfelt G. In: Isenberg D.A, Tucker L.B editor(s). Does the Black population in Africa get SLE? If not why not. London: Martin Dunitz Ltd, 1997.
39. Petri 2005 Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Hearth-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP. Combined oral contraceptives in women with systemic lupus erythematosus. New England Journal of Medicine 2005;353(24):2550-8.
40. Ruiz-Irastorza 2001 Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic Lupus Erythematosus. Lancet 2001; Vol. 357:1027-32. [MEDLINE: 65].
41. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408- 12.
42. Silman 1997 Silman A, Shipley M. Opthalmological monitoring for hydroxychloroquire toxicity: a scientific review of the available data. British Journal of Rheumatology 1997;36:599-601. [MEDLINE: 52].
43. Singh 1999 Singh G, Triadafilopoulos G. Epidemiology of NSAUD-induced gastrointestinal complications. Journal of Rheumatology 1999;26(Suppl 56):18-24. [MEDLINE: 49].
44. Strand 1999 Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. Journal of Rheumatology 1999;26(2):490-7.
45. Strand 1999b Strand V. Biologic agents and innovative interventional approaches in the management of systemic lupus erythematosus. Current Opinion in Rheumatology 1999;11(5):330-40. [MEDLINE: 35].
46. Strand 2004 Strand V. Clinical trial design in systemic lupus erythematosus: lessons learned and future directions. Lupus 2004;13(5):406-11. [MEDLINE: 59].
47. Tugwell 2004 Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, Wells G (Editors). Evidence-based Rheumatology. London: BMJ Books, 2004.
48. Whelton 2000 Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesia. American Journal of Therapeutics 2000;7:63-74. [MEDLINE: 50].
49. Wollaston 2004 Wollaston SJ, Farewell VT, Isenberg DA, Gordon C, Merrill JT, Petri MA, Kalunian KC. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. Journal of Rheumatology 2004;31(12):2390-4.